MannKind Beheer
Beheer criteriumcontroles 3/4
De CEO MannKind is Michael Castagna, benoemd in May2017, heeft een ambtstermijn van 7.5 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 7.07M, bestaande uit 9.9% salaris en 90.1% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.83% van de aandelen van het bedrijf, ter waarde $ 15.60M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 7.3 jaar en 4.8 jaar.
Belangrijke informatie
Michael Castagna
Algemeen directeur
US$7.1m
Totale compensatie
| Percentage CEO-salaris | 9.9% |
| Dienstverband CEO | 7.5yrs |
| Eigendom CEO | 0.8% |
| Management gemiddelde ambtstermijn | 7.3yrs |
| Gemiddelde ambtstermijn bestuur | 4.8yrs |
Recente managementupdates
Recent updates
MannKind Leverages Tyvaso DPI Strength In Pulmonary Market Expansion
Oct 03MannKind Corporation's (NASDAQ:MNKD) Share Price Boosted 28% But Its Business Prospects Need A Lift Too
Sep 18
Is There An Opportunity With MannKind Corporation's (NASDAQ:MNKD) 49% Undervaluation?
Jul 17MannKind Outperforms As Tyvaso DPI Captures Market Share
May 15This Just In: Analysts Are Boosting Their MannKind Corporation (NASDAQ:MNKD) Outlook for This Year
Mar 03MannKind Corporation (NASDAQ:MNKD) Surges 35% Yet Its Low P/S Is No Reason For Excitement
Mar 02MannKind's Tyvaso DPI Royalty Deal Signals Undervaluation
Feb 15MannKind Corporation's (NASDAQ:MNKD) Price Is Right But Growth Is Lacking
Jan 03Revenues Working Against MannKind Corporation's (NASDAQ:MNKD) Share Price
May 15MannKind Corporation's (NASDAQ:MNKD) Intrinsic Value Is Potentially 68% Above Its Share Price
Jan 27Mannkind Corporation: Ready For Your Biotech Portfolio
Sep 01New Forecasts: Here's What Analysts Think The Future Holds For MannKind Corporation (NASDAQ:MNKD)
Aug 19MannKind down 2% after Q2 2022 bottom line miss; however, net loss narrowed
Aug 09MannKind: What Do Pfizer, Sanofi, And MannKind Have In Common?
Feb 25MannKind: A Promising Player In The Inhalable Insulin Market
Feb 08US$6.17: That's What Analysts Think MannKind Corporation (NASDAQ:MNKD) Is Worth After Its Latest Results
Aug 14Lytham Partners Summer 2021 Investor Conference
Jun 14MannKind (MNKD) Investor Presentation - Slideshow
Jun 04MannKind reduces debt by $49.5M and restructures remaining obligations
Apr 26Did Business Growth Power MannKind's (NASDAQ:MNKD) Share Price Gain of 293%?
Feb 22MannKind to co-promote Thyquidity
Dec 17Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$22m |
| Jun 30 2024 | n/a | n/a | US$12m |
| Mar 31 2024 | n/a | n/a | US$8m |
| Dec 31 2023 | US$7m | US$702k | -US$12m |
| Sep 30 2023 | n/a | n/a | -US$31m |
| Jun 30 2023 | n/a | n/a | -US$47m |
| Mar 31 2023 | n/a | n/a | -US$71m |
| Dec 31 2022 | US$4m | US$623k | -US$87m |
| Sep 30 2022 | n/a | n/a | -US$98m |
| Jun 30 2022 | n/a | n/a | -US$88m |
| Mar 31 2022 | n/a | n/a | -US$94m |
| Dec 31 2021 | US$4m | US$598k | -US$81m |
| Sep 30 2021 | n/a | n/a | -US$79m |
| Jun 30 2021 | n/a | n/a | -US$86m |
| Mar 31 2021 | n/a | n/a | -US$61m |
| Dec 31 2020 | US$4m | US$495k | -US$57m |
| Sep 30 2020 | n/a | n/a | -US$45m |
| Jun 30 2020 | n/a | n/a | -US$44m |
| Mar 31 2020 | n/a | n/a | -US$46m |
| Dec 31 2019 | US$2m | US$511k | -US$52m |
| Sep 30 2019 | n/a | n/a | -US$47m |
| Jun 30 2019 | n/a | n/a | -US$61m |
| Mar 31 2019 | n/a | n/a | -US$71m |
| Dec 31 2018 | US$2m | US$500k | -US$87m |
| Sep 30 2018 | n/a | n/a | -US$110m |
| Jun 30 2018 | n/a | n/a | -US$119m |
| Mar 31 2018 | n/a | n/a | -US$131m |
| Dec 31 2017 | US$1m | US$459k | -US$117m |
Compensatie versus markt: De totale vergoeding ($USD 7.07M ) Michael } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 5.34M ).
Compensatie versus inkomsten: De vergoeding van Michael is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Michael Castagna (47 yo)
7.5yrs
Tenure
US$7,068,114
Compensatie
Dr. Michael E. Castagna, Pharm D., has been Chief Executive Officer of MannKind Corporation since May 25, 2017. Dr. Castagna served as Chief Commercial Officer of MannKind Corporation since March 14, 2016...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Director | 7.5yrs | US$7.07m | 0.83% $ 15.6m | |
| Chief Operating Officer | 1.7yrs | US$2.74m | 0.025% $ 478.2k | |
| Executive VP | 22.8yrs | US$2.34m | 0.17% $ 3.1m | |
| Executive VP and Chief People & Workplace Officer | 7.9yrs | US$2.22m | 0.22% $ 4.1m | |
| Chief Financial Officer | less than a year | geen gegevens | geen gegevens | |
| Executive Vice President of Technical Operations | 2.1yrs | US$1.12m | 0.035% $ 650.2k | |
| VP of Investor Relations & Treasury | 7.3yrs | US$519.59k | geen gegevens | |
| Senior Vice President of Worldwide Regulatory Affairs | 19.1yrs | geen gegevens | geen gegevens | |
| Chief Commercial Officer | 7.3yrs | US$921.51k | geen gegevens | |
| Executive VP of Research & Development and Chief Medical Officer | 1.5yrs | geen gegevens | 0.070% $ 1.3m |
7.3yrs
Gemiddelde duur
58yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van MNKD is doorgewinterd en ervaren (gemiddelde ambtstermijn van 7.3 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Director | 7.5yrs | US$7.07m | 0.83% $ 15.6m | |
| Independent Director | 21.1yrs | US$241.73k | 0.043% $ 805.2k | |
| Chairman Emeritus | less than a year | US$240.64k | 0.096% $ 1.8m | |
| Independent Director | 6yrs | US$226.73k | 0.010% $ 188.3k | |
| Independent Director | 20.9yrs | US$229.23k | 0.0054% $ 101.6k | |
| Independent Director | 4.8yrs | US$233.14k | 0.064% $ 1.2m | |
| Independent Chairman | 9.5yrs | US$255.64k | 0.0089% $ 166.3k | |
| Independent Director | 3.9yrs | US$221.73k | 0.039% $ 727.8k | |
| Member of Scientific Advisory Board | 3.3yrs | geen gegevens | geen gegevens | |
| Director | less than a year | US$2.34m | 0.20% $ 3.7m | |
| Independent Director | 4.7yrs | US$221.73k | 0.040% $ 752.7k | |
| Member of Scientific Advisory Board | 3.3yrs | geen gegevens | geen gegevens |
4.8yrs
Gemiddelde duur
64.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van MNKD wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.8 jaar).